-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The emergence of cell and gene therapy (CGT) has changed the way humans treat genetic diseases and intractable diseases
.
In recent years, with the continuous advancement of new CGT technology, new achievements have continued
.
Data shows that by the end of 2019, more than 27 CGT products have been launched globally, including Gilead, Novartis, Roche, Eli Lilly and BMS and other large pharmaceutical companies in this field
.
As of 2020, the number of CGT pipelines in the clinical stage worldwide is about 1,220, and the number of CGT drugs that are expected to be marketed in the next 3-5 years is expected to reach 76-110
.
With strong policy support, China has also become a fertile ground for the development of global CGT.
Local companies including WuXi AppTec, GenScript, Heyuan Biosciences, and Zhaoyan New Pharmaceutical are all rising rapidly, and the number of gene therapy clinical trials is increasing.
.
As of February 2021, a total of 658 gene therapy clinical trials have been registered globally, of which 40 are in China, accounting for 6.
1%
.
The industry predicts that with China’s accelerated review and approval and the increase in the number of patients with rare diseases, the scale of clinical research in this field will continue to expand
.
With the continuous growth of the gene cell therapy market, this field is also favored by investors.
Data shows that compared to 2014-2016, the amount of investment and financing in this field has shown explosive growth in 2018-2020
.
Among them, in 2020, the CGT field received US$19.
5 billion in financing, setting a new record since 2014
.
In China, there will be 41 financing transactions in 2020, involving more than 2.
4 billion U.
S.
dollars (15.
5 billion yuan)
.
Under the influence of policies and capital, the prosperity of the cell and gene therapy industry is expected to continue, and the CGTCDMO track is also favored by the industry
.
Recently, IFC issued a research report saying that with the continuous advancement of CGT new technology, the ceiling of market capacity has gradually opened.
.
According to Frost&Sullivan's calculations, the global CGT market has rapidly increased from US$50 million in 2016 to US$2.
08 billion in 2020, and is expected to exceed the US$30 billion mark in 2025
.
In addition, benefiting from the increase in outsourcing penetration and the expansion of the CGT industry, the market size of CRO&CDMO in the CGT field has also increased rapidly, and the market size is expected to reach 1.
74 billion US dollars in 2025
.
From the research report, the organization is optimistic about WuXiATU, WuXiATU, WuXiATU's cell and gene therapy business platform, and believes that its unique CTDMO (contract testing, development, production outsourcing service) business model can better cope with the current CGT field testing and development And release the complexity and difficulty of the problem, effectively solve the cost problem of scale-up production
.
In addition, WuXiATU has further strengthened the company’s AAV and lentivirus platform technical capabilities through the acquisition of OXGENE, and recently announced that the new bases in Philadelphia and Lingang have been put into operation, simultaneously increasing the talent pool.
It is expected that China will have 300-400 employees by the end of 2021.
It will grow to 700-800 employees in 2022
.
In this regard, China International Finance Securities expressed optimism about WuXiATU's future development potential, and its performance is expected to grow rapidly
.
In addition to Guojin Securities, some investors also expressed optimism about the CGTCDMO track
.
He pointed out that compared with the small molecule and macromolecule CDMO industry, the CGTCDMO industry has higher barriers and more difficult production process development and amplification, so it may have a faster growth rate and better investment prospects
.
It is predicted that in 2030, the domestic domestic CGTCDMO market is expected to reach 12.
3 billion yuan
.
The 2020-2025 CAGR is 50%, and the 2025-2030 CAGR is 31%
.
The head of the enterprise on the recommendations concern the track, such as WuXi, and biological yuan, Jin Ruisi, Bo Teng shares into Hong Long and so on
.
.
In recent years, with the continuous advancement of new CGT technology, new achievements have continued
.
Data shows that by the end of 2019, more than 27 CGT products have been launched globally, including Gilead, Novartis, Roche, Eli Lilly and BMS and other large pharmaceutical companies in this field
.
As of 2020, the number of CGT pipelines in the clinical stage worldwide is about 1,220, and the number of CGT drugs that are expected to be marketed in the next 3-5 years is expected to reach 76-110
.
With strong policy support, China has also become a fertile ground for the development of global CGT.
Local companies including WuXi AppTec, GenScript, Heyuan Biosciences, and Zhaoyan New Pharmaceutical are all rising rapidly, and the number of gene therapy clinical trials is increasing.
.
As of February 2021, a total of 658 gene therapy clinical trials have been registered globally, of which 40 are in China, accounting for 6.
1%
.
The industry predicts that with China’s accelerated review and approval and the increase in the number of patients with rare diseases, the scale of clinical research in this field will continue to expand
.
With the continuous growth of the gene cell therapy market, this field is also favored by investors.
Data shows that compared to 2014-2016, the amount of investment and financing in this field has shown explosive growth in 2018-2020
.
Among them, in 2020, the CGT field received US$19.
5 billion in financing, setting a new record since 2014
.
In China, there will be 41 financing transactions in 2020, involving more than 2.
4 billion U.
S.
dollars (15.
5 billion yuan)
.
Under the influence of policies and capital, the prosperity of the cell and gene therapy industry is expected to continue, and the CGTCDMO track is also favored by the industry
.
Recently, IFC issued a research report saying that with the continuous advancement of CGT new technology, the ceiling of market capacity has gradually opened.
.
According to Frost&Sullivan's calculations, the global CGT market has rapidly increased from US$50 million in 2016 to US$2.
08 billion in 2020, and is expected to exceed the US$30 billion mark in 2025
.
In addition, benefiting from the increase in outsourcing penetration and the expansion of the CGT industry, the market size of CRO&CDMO in the CGT field has also increased rapidly, and the market size is expected to reach 1.
74 billion US dollars in 2025
.
From the research report, the organization is optimistic about WuXiATU, WuXiATU, WuXiATU's cell and gene therapy business platform, and believes that its unique CTDMO (contract testing, development, production outsourcing service) business model can better cope with the current CGT field testing and development And release the complexity and difficulty of the problem, effectively solve the cost problem of scale-up production
.
In addition, WuXiATU has further strengthened the company’s AAV and lentivirus platform technical capabilities through the acquisition of OXGENE, and recently announced that the new bases in Philadelphia and Lingang have been put into operation, simultaneously increasing the talent pool.
It is expected that China will have 300-400 employees by the end of 2021.
It will grow to 700-800 employees in 2022
.
In this regard, China International Finance Securities expressed optimism about WuXiATU's future development potential, and its performance is expected to grow rapidly
.
In addition to Guojin Securities, some investors also expressed optimism about the CGTCDMO track
.
He pointed out that compared with the small molecule and macromolecule CDMO industry, the CGTCDMO industry has higher barriers and more difficult production process development and amplification, so it may have a faster growth rate and better investment prospects
.
It is predicted that in 2030, the domestic domestic CGTCDMO market is expected to reach 12.
3 billion yuan
.
The 2020-2025 CAGR is 50%, and the 2025-2030 CAGR is 31%
.
The head of the enterprise on the recommendations concern the track, such as WuXi, and biological yuan, Jin Ruisi, Bo Teng shares into Hong Long and so on
.
